|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
33,650,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Frequency Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics to activate a person's innate regenerative potential to restore function. Co. develops FX-322 to treat an underlying cause of sensorineural hearing loss, which is the loss of hair cells. Co.'s proprietary approach, Progenitor Cell Activation, uses small molecules to activate progenitor cells within the body to create functional tissue. These progenitor cells, which are closely related to stem cells, are already resident in the targeted location in the body and programmed to develop and differentiate into specific cell types within an organ.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
178,570 |
178,570 |
178,570 |
178,570 |
Total Buy Value |
$9,999,920 |
$9,999,920 |
$9,999,920 |
$9,999,920 |
Total People Bought |
10 |
10 |
10 |
10 |
Total Buy Transactions |
10 |
10 |
10 |
10 |
Total Shares Sold |
0 |
0 |
134,724 |
157,951 |
Total Sell Value |
$0 |
$0 |
$154,141 |
$189,534 |
Total People Sold |
0 |
0 |
3 |
6 |
Total Sell Transactions |
0 |
0 |
94 |
99 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lucchino David L. |
President and CEO |
|
2021-02-01 |
4 |
AS |
$41.29 |
$1,426,370 |
D/D |
(33,102) |
308,086 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2021-02-01 |
4 |
OE |
$0.61 |
$20,192 |
D/D |
33,102 |
341,188 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2021-01-27 |
4 |
AS |
$42.50 |
$390,830 |
D/D |
(9,196) |
308,086 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2021-01-27 |
4 |
OE |
$0.61 |
$5,610 |
D/D |
9,196 |
317,282 |
|
- |
|
Loose Christopher R. |
Chief Scientific Officer |
|
2021-01-27 |
4 |
AS |
$42.50 |
$340,000 |
D/D |
(8,000) |
31,782 |
|
- |
|
Bookman Michael |
General Counsel and SecretaryO |
|
2021-01-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,236 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2021-01-06 |
4 |
AS |
$36.13 |
$1,063,917 |
D/D |
(27,586) |
308,086 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2021-01-06 |
4 |
OE |
$0.61 |
$16,827 |
D/D |
27,586 |
335,672 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2021-01-04 |
4 |
AS |
$32.89 |
$1,132,740 |
D/D |
(34,104) |
308,086 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2021-01-04 |
4 |
OE |
$0.61 |
$11,218 |
D/D |
18,390 |
342,190 |
|
- |
|
Marcus Joel S |
Director |
|
2020-12-22 |
4 |
S |
$32.09 |
$672,134 |
D/D |
(20,000) |
270,000 |
|
- |
|
Marcus Joel S |
Director |
|
2020-12-21 |
4 |
S |
$30.35 |
$303,521 |
D/D |
(10,000) |
290,000 |
|
- |
|
Marcus Joel S |
Director |
|
2020-12-18 |
4 |
S |
$33.92 |
$726,757 |
D/D |
(19,700) |
300,000 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-17 |
4 |
AS |
$42.64 |
$47,755 |
D/D |
(1,120) |
323,800 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-17 |
4 |
OE |
$0.61 |
$683 |
D/D |
1,120 |
324,920 |
|
- |
|
Loose Christopher R. |
Chief Scientific Officer |
|
2020-12-17 |
4 |
AS |
$40.00 |
$325,001 |
D/D |
(8,000) |
39,782 |
|
- |
|
Loose Christopher R. |
Chief Scientific Officer |
|
2020-12-16 |
4 |
AS |
$37.87 |
$311,480 |
D/D |
(8,000) |
47,782 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-16 |
4 |
AS |
$40.00 |
$540,560 |
D/D |
(13,514) |
323,800 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-16 |
4 |
OE |
$0.61 |
$8,244 |
D/D |
13,514 |
337,314 |
|
- |
|
Loose Christopher R. |
Chief Scientific Officer |
|
2020-12-15 |
4 |
AS |
$37.28 |
$298,240 |
D/D |
(8,000) |
55,782 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-15 |
4 |
AS |
$38.18 |
$518,890 |
D/D |
(13,514) |
323,800 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-15 |
4 |
OE |
$0.61 |
$8,244 |
D/D |
13,514 |
337,314 |
|
- |
|
Loose Christopher R. |
Chief Scientific Officer |
|
2020-12-14 |
4 |
AS |
$35.00 |
$280,000 |
D/D |
(8,000) |
63,782 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-14 |
4 |
AS |
$35.12 |
$474,612 |
D/D |
(13,514) |
323,800 |
|
- |
|
Lucchino David L. |
President and CEO |
|
2020-12-14 |
4 |
OE |
$0.61 |
$8,244 |
D/D |
13,514 |
337,314 |
|
- |
|
299 Records found
|
|
Page 9 of 12 |
|
|